ArticleBioengineering & translational medicine2023

Engineering T cell receptor fusion proteins using nonviral CRISPR/Cas9 genome editing for cancer immunotherapy.

Runzhe Shu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.